Adenosine and protection from acute kidney injury

Current Opinion in Nephrology and Hypertension

Volumn 21, Issue 1, 2012, Pages 24-32

  Yap, Steven C ^a   Thomas Lee, H ^a  

^a Columbia University ^*  (United States)

Author keywords

apoptosis; inflammation; ischemia and reperfusion injury; necrosis

Indexed keywords

5' NUCLEOTIDASE; 6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR AGONIST; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR STIMULATING AGENT; ADENOSINE TRIPHOSPHATE; BAY 60 6583; CD39 ANTIGEN; CISPLATIN; CREATININE; GENTAMICIN; GLYCEROL; HEAT SHOCK PROTEIN 27; MITOGEN ACTIVATED PROTEIN KINASE; NEPHROTOXIC AGENT; NITRIC OXIDE; PROTEIN KINASE B; RENIN; THEOPHYLLINE; TOXIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; URANYL NITRATE;

ACUTE KIDNEY FAILURE; APOPTOSIS; CONGESTIVE HEART FAILURE; CONTRAST INDUCED NEPHROPATHY; CREATININE BLOOD LEVEL; DISEASE DURATION; EXTRACELLULAR SPACE; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; HUMAN; HYDROLYSIS; KIDNEY BLOOD FLOW; KIDNEY DYSFUNCTION; KIDNEY ISCHEMIA; KIDNEY PERFUSION; LIVER ISCHEMIA; LIVER PROTECTION; MAST CELL DEGRANULATION; NEPHROTOXICITY; NONHUMAN; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY; PHARMACOLOGICAL STIMULATION; PHOSPHOHYDROLYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION; RENAL PROTECTION; RENIN RELEASE; REPERFUSION INJURY; REVIEW; SEPTIC SHOCK; SIGNAL TRANSDUCTION; SYSTEMIC DISEASE; UNSPECIFIED SIDE EFFECT; URINE VOLUME; VASODILATATION;

ACUTE KIDNEY INJURY; ADENOSINE; ANIMALS; CYTOPROTECTION; HUMANS; KIDNEY; PURINERGIC P1 RECEPTOR AGONISTS; PURINERGIC P1 RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P1; SIGNAL TRANSDUCTION;

EID: 83055186461     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32834d2ec9     Document Type: Review

References (66)

1. Chertow GM, Burdick E, Honour M, et al. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005; 16:3365-3370. (Pubitemid 46179340)
2. Jones DR, Lee HT. Perioperative renal protection. Best Pract Res Clin Anaesthesiol 2008; 22:193-208. (Pubitemid 351405119)
3. Srisawat N, Hoste EE, Kellum JA. Modern classification of acute kidney injury. Blood Purif 2010; 29:300-307.
4. Hoste EA, Kellum JA, Katz NM, et al. Epidemiology of acute kidney injury. Contrib Nephrol 2010; 165:1-8.
5. Kellum JA, Hoste EA. Acute kidney injury: epidemiology and assessment. Scand J Clin Lab Invest Suppl 2008; 241:6-11. (Pubitemid 351883670)
6. Hoste EA, Kellum JA. Incidence, classification, and outcomes of acute kidney injury. Contrib Nephrol 2007; 156:32-38.
7. Sheridan AM, Bonventre JV. Cell biology and molecular mechanisms of injury in ischemic acute renal failure. Curr Opin Nephrol Hypertens 2000; 9:427-434. (Pubitemid 30451699)
8. Bauerle JD, Grenz A, Kim JH, et al. Adenosine generation and signaling during acute kidney injury. J Am Soc Nephrol 2011; 22:14-20.
9. Okusa MD. The changing pattern of acute kidney injury: from one to multiple organ failure. Contrib Nephrol 2010; 165:153-158.
10. Paladino JD, Hotchkiss JR, Rabb H. Acute kidney injury and lung dysfunction: a paradigm for remote organ effects of kidney disease? Microvasc Res 2009; 77:8-12.
11. Faubel S. Pulmonary complications after acute kidney injury. Adv Chronic Kidney Dis 2008; 15:284-296. (Pubitemid 351822597)
12. Bagshaw SM, Laupland KB, Doig CJ, et al. Prognosis for long-term survival and renal recovery in critically ill patients with severe acute renal failure: a population-based study. Crit Care 2005; 9:R700-R709.
13. Vallon V, Osswald H. Adenosine receptors and the kidney. Handb Exp Pharmacol 2009; 193:443-470.
14. Vallon V, Muhlbauer B, Osswald H. Adenosine and kidney function. Physiol Rev 2006; 86:901-940. (Pubitemid 44033385)
15. McDonald B, Pittman K, Menezes GB, et al. Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science 2010; 330:362-366.
16. Thompson LF, Eltzschig HK, Ibla JC, et al. Crucial role for ecto-50-nucleotidase (CD73) in vascular leakage during hypoxia. J Exp Med 2004; 200:1395-1405. (Pubitemid 39657287)
17. Eltzschig HK, Kohler D, Eckle T, et al. Central role of Sp1-regulated CD39 in hypoxia/ischemia protection. Blood 2009; 113:224-232.
18. Grenz A, Zhang H, Hermes M, et al. Contribution of E-NTPDase1 (CD39) to renal protection from ischemia-reperfusion injury. FASEB J 2007; 21:2863-2873. (Pubitemid 47372753)
19. Grenz A, Zhang H, Eckle T, et al. Protective role of ecto-50-nucleotidase (CD73) in renal ischemia. J Am Soc Nephrol 2007; 18:833-845. (Pubitemid 46434500)
20. Trautmann A. Extracellular ATP in the immune system: more than just a 'danger signal'. Sci Signal 2009; 2:e6.
21. Chen Y, Corriden R, Inoue Y, et al. ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science 2006; 314:1792-1795. (Pubitemid 44969094)
22. Stagg J, Smyth MJ. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 2010; 29:5346-5358.
23. Fredholm BB, Irenius E, Kull B, Schulte G. Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. Biochem Pharmacol 2001; 61:443-448. (Pubitemid 32168226)
24. Fredholm BB. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ 2007; 14:1315-1323. (Pubitemid 46965261)
25. Joo JD, Kim M, Horst P, et al. Acute and delayed renal protection against renal ischemia and reperfusion injury with A1 adenosine receptors. Am J Physiol Renal Physiol 2007; 293:F1847-F1857. (Pubitemid 350179610)
26. Kim M, Chen SW, Park SW, et al. Kidney-specific reconstitution of the A1 adenosine receptor in A1 adenosine receptor knockout mice reduces renal ischemia-reperfusion injury. Kidney Int 2009; 75:809-823.
27. Lee HT, Kim M, Jan M, et al. Renal tubule necrosis and apoptosis modulation by A1 adenosine receptor expression. Kidney Int 2007; 71:1249-1261. (Pubitemid 46884252)
28. Gallos G, Ruyle TD, Emala CW, Lee HT. A1 adenosine receptor knockout mice exhibit increased mortality, renal dysfunction, and hepatic injury in murine septic peritonitis. Am J Physiol Renal Physiol 2005; 289:F369-F376. (Pubitemid 41003666)
29. Lee HT, Gallos G, Nasr SH, Emala CW. A1 adenosine receptor activation inhibits inflammation, necrosis, and apoptosis after renal ischemia-reperfusion injury in mice. J Am Soc Nephrol 2004; 15:102-111. (Pubitemid 38020702)
30. Lee HT, Xu H, Nasr SH, et al. A1 adenosine receptor knockout mice exhibit increased renal injury following ischemia and reperfusion. Am J Physiol Renal Physiol 2004; 286:F298-F306. (Pubitemid 38141673)
31. Lee HT, Jan M, Bae SC, et al. A1 adenosine receptor knockout mice are protected against acute radiocontrast nephropathy in vivo. Am J Physiol Renal Physiol 2006; 290:F1367-F1375. (Pubitemid 43830761)
32. Gottlieb SS. Adenosine A1 antagonists and the cardiorenal syndrome. Curr Heart Fail Rep 2008; 5:105-109.
33. Gottlieb SS, Brater DC, Thomas I, et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 2002; 105:1348-1353. (Pubitemid 34260427)
34. Voors AA, Dittrich HC, Massie BM, et al. Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function). J Am Coll Cardiol 2011; 57:1899-1907.
35. Osswald H, Schnermann J. Methylxanthines and the kidney. Handb Exp Pharmacol 2011; 200:391-412.
36. Asif A, Epstein M. Prevention of radiocontrast-induced nephropathy. Am J Kidney Dis 2004; 44:12-24. (Pubitemid 38880922)
37. Okusa MD. A(2A) adenosine receptor: a novel therapeutic target in renal disease. Am J Physiol Renal Physiol 2002; 282:F10-F18. (Pubitemid 34654194)
38. Okusa MD, Linden J, Huang L, et al. A(2A) adenosine receptor-mediated inhibition of renal injury and neutrophil adhesion. Am J Physiol Renal Physiol 2000; 279:F809-F818.
39. Lee HT, Emala CW. Adenosine attenuates oxidant injury in human kidney proximal tubular cells via A1 and A2a adenosine receptor activation. Am J Physiol Renal Physiol 2002; 282:F844-F852. (Pubitemid 34654490)
40. Lee HT, Emala CW. Systemic adenosine given after ischemia protects renal function via A2a adenosine receptor activation. Am J Kidney Dis 2001; 38:610-618. (Pubitemid 32803074)
41. Day YJ, Huang L, McDuffie MJ, et al. Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells. J Clin Invest 2003; 112:883-891. (Pubitemid 38063746)
42. Day YJ, Huang L, Ye H, et al. Renal ischemia-reperfusion injury and adenosine 2A receptor-mediated tissue protection: role of macrophages. Am J Physiol Renal Physiol 2005; 288:F722-F731. (Pubitemid 40381739)
43. Garcia GE, Truong LD, Li P, et al. Adenosine A2A receptor activation and macrophage-mediated experimental glomerulonephritis. FASEB J 2008; 22:445-454. (Pubitemid 351225581)
44. Eckle T, Faigle M, Grenz A, et al. A2B adenosine receptor dampens hypoxiainduced vascular leak. Blood 2008; 111:2024-2035. (Pubitemid 351451513)
45. Linden J. New insights into the regulation of inflammation by adenosine. J Clin Invest 2006; 116:1835-1837. (Pubitemid 44033306)
46. Grenz A, Osswald H, Eckle T, et al. The reno-vascular A2B adenosine receptor protects the kidney from ischemia. PLoS Med 2008; 5:e137.
47. Linden J. Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol 2001; 41:775-787. (Pubitemid 32385906)
48. Mozaffari MS, Abebe W, Warren BK. Renal adenosine A3 receptors in the rat: assessment of functional role. Can J Physiol Pharmacol 2000; 78:428-432. (Pubitemid 30354467)
49. Young HW, Molina JG, Dimina D, et al. A3 adenosine receptor signaling contributes to airway inflammation and mucus production in adenosine deaminase-deficient mice. J Immunol 2004; 173:1380-1389. (Pubitemid 38924319)
50. Lee HT, Ota-Setlik A, Xu H, et al. A3 adenosine receptor knockout mice are protected against ischemia-and myoglobinuria-induced renal failure. Am J Physiol Renal Physiol 2003; 284:F267-F273. (Pubitemid 36114689)
51. Mabley J, Soriano F, Pacher P, et al. The adenosine A3 receptor agonist, N6-(3-iodobenzyl)-adenosine-50-N-methyluronamide, is protective in two murine models of colitis. Eur J Pharmacol 2003; 466:323-329. (Pubitemid 36412095)
52. Lee HT, Emala CW. Protective effects of renal ischemic preconditioning and adenosine pretreatment: role of A(1) and A(3) receptors. Am J Physiol Renal Physiol 2000; 278:F380-F387. (Pubitemid 30163237)
53. Lee HT, Kim M, Joo JD, et al. A3 adenosine receptor activation decreases mortality and renal and hepatic injury in murine septic peritonitis. Am J Physiol Regul Integr Comp Physiol 2006; 291:R959-R969. (Pubitemid 44498436)
54. Reeves JJ, Jones CA, Sheehan MJ, et al. Adenosine A3 receptors promote degranulation of rat mast cells both in vitro and in vivo. Inflamm Res 1997; 46:180-184. (Pubitemid 27248399)
55. Fozard JR, Pfannkuche HJ, Schuurman HJ. Mast cell degranulation following adenosine A3 receptor activation in rats. Eur J Pharmacol 1996; 298:293-297. (Pubitemid 26096404)
56. Shneyvays V, Nawrath H, Jacobson KA, Shainberg A. Induction of apoptosis in cardiac myocytes by an A3 adenosine receptor agonist. Exp Cell Res 1998; 243:383-397. (Pubitemid 28488849)
57. Jacobson KA. Adenosine A3 receptors: novel ligands and paradoxical effects. Trends Pharmacol Sci 1998; 19:184-191. (Pubitemid 28255405)
58. Kohno Y, Sei Y, Koshiba M, et al. Induction of apoptosis in HL-60 human promyelocytic leukemia cells by adenosine A3 receptor agonists. Biochem Biophys Res Commun 1996; 232:904-910. (Pubitemid 26106777)
59. Zhao Z, Yaar R, Ladd D, et al. Overexpression of A3 adenosine receptors in smooth, cardiac, and skeletal muscle is lethal to embryos. Microvasc Res 2002; 63:61-69. (Pubitemid 34971509)
60. Levy RM, Mollen KP, Prince JM, et al. Systemic inflammation and remote organ injury following trauma require HMGB1. Am J Physiol Regul Integr Comp Physiol 2007; 293:R1538-R1544. (Pubitemid 47535772)
61. Park SW, Chen SW, Kim M, et al. Cytokines induce small intestine and liver injury after renal ischemia or nephrectomy. Lab Invest 2011; 91:63-84.
62. Park SW, Chen SW, Kim M, et al. Protection against acute kidney injury via A(1) adenosine receptor-mediated Akt activation reduces liver injury after liver ischemia and reperfusion in mice. J Pharmacol Exp Ther 2010; 333:736-747.
63. Park SW, Chen SW, Kim M, et al. Selective intrarenal human A1 adenosine receptor overexpression reduces acute liver and kidney injury after hepatic ischemia reperfusion in mice. Lab Invest 2010; 90:476-495.
64. Lee HT, Park SW, Kim M, D'Agati VD. Acute kidney injury after hepatic ischemia and reperfusion injury in mice. Lab Invest 2009; 89: 196-208.
65. Kiesman WF, Elzein E, Zablocki J. A1 adenosine receptor antagonists, agonists, and allosteric enhancers. Handb Exp Pharmacol 2009; 193:25-58.
66. Baraldi PG, Iaconinoto MA, Moorman AR, et al. Allosteric enhancers for A1 adenosine receptor. Mini Rev Med Chem 2007; 7:559-569.